Document is current
Any future updates will be listed below
-
Authors
Colwell, Michael J. https://orcid.org/0000-0001-7846-2879
van Uum, Fin J. E.
Cowen, Philip J. https://orcid.org/0000-0001-5518-6138
Martens, Marieke A. G.
Browning, Michael https://orcid.org/0000-0001-9108-3144
Barron, Helen C. https://orcid.org/0000-0002-4575-6472
Harmer, Catherine J. https://orcid.org/0000-0002-1609-8335
Murphy, Susannah E.
- License Information
-
More Information
Article History
Received: 17 March 2026
Accepted: 15 May 2026
First Online: 2 June 2026
Competing interests
: C.H. has received consultancy fees from P1vital Ltd., Janssen Pharmaceuticals, UCB, Compass Pathways, and Lundbeck. She is a co-director of TnC Psychiatry and Neuroscience. S.M. has received consultancy fees from Zogenix, Sumitomo Dainippon Pharma, P1vital Ltd. and Johnson & Johnson Pharmaceuticals. C.H. and S.M. recently held grant income from Zogenix, UCB Pharma and Janssen Pharmaceuticals. C.H., S.M. and P.C. recently held grant income from a collaborative research project with Pfizer. M.B. reports grants from the Wellcome Trust, Medical Research Council, Office for Life Science and National Institute for Health and Care Research (NIHR); consulting fees from Janssen, CHDR, Engrail Therapeutics, Boehringer, P1vital, Alto Neuroscience, and Empyrean Therapeutics; and was previously employed by P1vital. The first and corresponding author (M.C.), alongside other authors, report no conflicts of interest.
